Protocol Ledger

NCT07565428 · Phase III · RECRUITING

Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications

Interventional Phase III clinical trial protocol NCT07565428 sponsored by Minerva Neurosciences in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-23 Enrollment: 380 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07565428
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)380 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07565428
Protocol FieldVerified Registry Value
NCT IdentifierNCT07565428
Consolidated Lead SponsorMinerva Neurosciences
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment380 participants (ESTIMATED)
Registered Start Date2026-04-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07565428
Hospital Research SiteLocationSite Profile
ProScience Research GroupCulver City, CAOpen Hospital Dossier ->
ForCare Clinical ResearchTampa, FLOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI